Small-volume ELISA Correlia Biosystems recently launched an ELISA platform tailored for small sample volumes, indicating a potential fit for customers seeking cost-efficient, low-volume biomarker assays and rapid results.

High-speed microscale The PIXI platform accelerates molecular interaction measurements from sub-2 microliter samples, presenting opportunities to upsell to labs needing rapid turnover, high-throughput screening, or dynamic protein expression profiling.

Berkeley momentum With a Series A completed in 2020 and ongoing fundraising activity, there is momentum and credibility for engaging early-stage biotech teams, contract research organizations, and academic labs seeking innovative instrumentation.

CRM and analytics Adoption of HubSpot Analytics and cloud-based tech stack suggests readiness for targeted outbound campaigns, account-based sales, and data-driven lead nurturing within biotech and life sciences segments.

Growth-ready markets Revenue in the low-to-mid single digits and a small employee base implies a focus on strategic partnerships or pilot programs with larger CROs, biotechs, or diagnostic developers looking to scale with specialized microscale tools.